|Ms. Julie H. McHugh||Exec. Chairman||95k||N/A||1964|
|Mr. Thomas A. McCourt||CEO & Director||944.57k||284.33k||1957|
|Mr. Jason Rickard||COO & Sr. VP of Operations||940.06k||N/A||1971|
|Dr. Michael Shetzline M.D., Ph.D.||Chief Medical Officer, Sr. VP and Head of R&D||770.28k||N/A||1959|
|Mr. Brian M. Cali||Co-Founder and Sr. VP of R&D Strategy & External Innovation||N/A||N/A||N/A|
|Mr. G. Todd Milne||Co-Founder and VP of sGC R&D||N/A||N/A||N/A|
|Mr. Ronald Silver||Corp. Controller & Principal Accounting Officer||N/A||N/A||1982|
|Mr. John Minardo||Sr. VP & Chief Legal Officer||N/A||N/A||N/A|
|Mr. Jonathan Rosin||Sr. VP of HR||N/A||N/A||N/A|
|Dr. Christopher I. Wright||Chief Devel. Officer & Sr. VP of Global Devel.||N/A||N/A||N/A|
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Ironwood Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 July 2021 is 3. The pillar scores are Audit: 3; Board: 1; Shareholder rights: 6; Compensation: 5.